Rituximab-containing Chemotherapy (R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma

Hiroshi Ureshino; Toshihiko Ando; Kensuke Kojima; Hidekazu Itamura; Shunichi Jinnai; Kazuko Doi; Koichi Ohshima; Kazuya Kurogi; Masaharu Miyahara; Shinya Kimura

doi:10.2169/internalmedicine.54.5103

CASE REPORTS

Rituximab-containing Chemotherapy (R-CHOP)-induced Kaposi's Sarcoma in an HIV-negative Patient with Diffuse Large B Cell Lymphoma

Hiroshi Ureshino, Toshihiko Ando, Kensuke Kojima, Hidekazu Itamura, Shunichi Jinnai, Kazuko Doi, Koichi Ohshima, Kazuya Kurogi, Masaharu Miyahara, Shinya Kimura

Author information

Hiroshi Ureshino
Department of Internal Medicine, Karatsu Red Cross Hospital, Japan
Toshihiko Ando
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan
Kensuke Kojima
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan
Hidekazu Itamura
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan
Shunichi Jinnai
Department of Dermatology, Karatsu Red Cross Hospital, Japan
Kazuko Doi
Department of Dermatology, Karatsu Red Cross Hospital, Japan
Koichi Ohshima
Department of Pathology, School of Medicine, Kurume University, Japan
Kazuya Kurogi
Department of Internal Medicine, Karatsu Red Cross Hospital, Japan
Masaharu Miyahara
Department of Internal Medicine, Karatsu Red Cross Hospital, Japan
Shinya Kimura
Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Japan

Keywords: diffuse large B cell lymphoma, rituximab, Kaposi's sarcoma, HIV, pneumonia

JOURNAL OPEN ACCESS

2015 Volume 54 Issue 24 Pages 3205-3208

DOI https://doi.org/10.2169/internalmedicine.54.5103

Details

Abstract

Rituximab treatment may cause or exacerbate Kaposi's sarcoma (KS) in patients with human immunodeficiency virus (HIV)-associated multicentric Castleman's disease. Despite the widespread use of rituximab, rituximab-induced KS has not yet been reported in HIV-negative patients with diffuse large B cell lymphoma (DLBCL). We herein report a case of KS that developed after undergoing rituximab-containing chemotherapy in an HIV-negative patient with DLBCL. An 84-year-old man who received rituximab-containing chemotherapy for the treatment of DLBCL developed severe infection, and subsequently KS. Our observations indicate that serious infections under rituximab treatment may trigger KS. KS should therefore be considered when skin tumors appear in lymphoma patients receiving rituximab-containing chemotherapy.

Corresponding author

Register with J-STAGE for free!